Company: IXHL
Filing Date: 2025-04-16
Form Type: S-1/A
Source: 0001213900-25-032577
Chunk: 30

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-16
Form: S-1/A
Chunk 30
---
902,171 shares are currently available for such issuance out of our authorized shares of
Common Stock. As such, we are only seeking to register 64,328,081 shares of our Common Stock issuable upon exercise of the Series A Warrants
pursuant to the registration statement on Form S-1 of which this prospectus is a part. Following and assuming approval of the Charter
Amendment Proposal, we will seek to register the remaining 282,894,619 shares of our Common Stock issuable upon exercise of the Series
A Warrants.

The selling stockholders
may offer and sell, from time to time, any or the Shares described under the column “Number of Shares of Shares Being Offered”
in the table below. Except for the ownership of the securities, the selling stockholders have not had any material relationship with us
within the past three years.

As used in this prospectus,
the term “selling stockholders” includes the selling stockholders listed in the table below, together with any additional
selling stockholders listed in a subsequent amendment to this prospectus, and their donees, pledgees, assignees, transferees, distributees
and successors-in-interest that receive shares in any non-sale transfer after the date of this prospectus.

The table below lists the
selling stockholders and other information regarding the beneficial ownership of the Shares by each of the selling stockholders as of
April 9, 2025. The following table also provides the number of Shares that may be sold by each selling stockholder under this prospectus
and that each selling stockholder will beneficially own assuming all the Shares that may be offered pursuant to this prospectus are sold.
The number of shares described under the column “Shares of Common Stock Beneficially Owned Before this Offering” for each
selling stockholder includes all shares of our Common Stock beneficially held by such selling stockholder as of April 9, 2025, which
includes (i) all shares of our Common Stock purchased by such selling stockholder in the Private Placement, and (ii) all of the shares
of Common Stock issuable upon exercise of the Pre-Funded Warrants purchased by such selling stockholder in the Private Placement, subject
to the Beneficial Ownership Limitation, and excludes shares of Common Stock issuable upon exercise of the Series A Warrants purchased
by such selling stockholder in the Private Placement, the exercise of which is subject to the Beneficial Ownership Limitation and Stockholder
Approval.